<DOC>
	<DOCNO>NCT00139152</DOCNO>
	<brief_summary>The purpose study study effect Xolair use non-invasive technique expire gas patient moderate severe allergic asthma .</brief_summary>
	<brief_title>Non-invasive Ways Evaluate Lung Disease After Treatment With Xolair</brief_title>
	<detailed_description>Traditional method sample secretion low respiratory tract include sputum collection , sputum induction , bronchoscopy bronchoalveolar lavage . They repeat within short period time invasiveness , procedure may include inflammatory response . The need monitor inflammation lung lead exploration exhale gas condensate . Noninvasive monitoring may assist differential diagnosis pulmonary disease , assessment disease severity response treatment .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>On medium high dose inhale corticosteroid either without long act beta agonist Baseline IgE 30700 IU/mL Exhaled nitric oxide great 13 ppb Positive skin test least one follow perennial allergen : cat , dog , dust mite , cockroach Stable asthma time enrollment Concurrent diseases/conditions , history diseases/conditions , clinically significant uncontrolled systemic disease history disease ( eg , infection , hematological , renal , hepatic , coronary heart disease cardiovascular disease , endocrinological , gastrointestinal disease ) within previous 3 month Upper low respiratory tract infection within 6 week screen visit Elevated IgE level atopy Known sensitivity Xolair &lt; 3 month stable immunotherapy Smokers Pregnant/nursing woman Women childbearing potential practicing medically approve contraceptive method ( eg , oral , subcutaneous , mechanical , surgical contraception ) include abstinence Patients currently hav diagnosed cancer , currently investigate possible cancer history cancer Known sensitivity study drug class study drug Patients severe medical condition ( ) view investigator prohibit participation study Use investigational agent last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>moderate severe allergic asthma</keyword>
</DOC>